143 related articles for article (PubMed ID: 25911860)
1. K-Ras mutation and prognosis of colorectal cancer: a meta-analysis.
Rui Y; Wang C; Zhou Z; Zhong X; Yu Y
Hepatogastroenterology; 2015; 62(137):19-24. PubMed ID: 25911860
[TBL] [Abstract][Full Text] [Related]
2. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
3. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
[TBL] [Abstract][Full Text] [Related]
4. Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.
Bösmüller H; Kranewitter W; Webersinke G; Rumpold H; Hackl M; Fend F
Pathol Res Pract; 2011 Jun; 207(6):399-402. PubMed ID: 21536390
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
6. Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum.
Kaji E; Kato J; Suzuki H; Akita M; Horii J; Saito S; Higashi R; Ishikawa S; Kuriyama M; Hiraoka S; Uraoka T; Yamamoto K
J Gastroenterol Hepatol; 2011 Mar; 26(3):599-607. PubMed ID: 21332555
[TBL] [Abstract][Full Text] [Related]
7. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis.
Ren J; Li G; Ge J; Li X; Zhao Y
Dis Colon Rectum; 2012 Aug; 55(8):913-23. PubMed ID: 22810479
[TBL] [Abstract][Full Text] [Related]
8. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
9. High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.
Ilm K; Kemmner W; Osterland M; Burock S; Koch G; Herrmann P; Schlag PM; Stein U
Mol Cancer; 2015 Feb; 14():38. PubMed ID: 25742883
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
[TBL] [Abstract][Full Text] [Related]
11. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
[TBL] [Abstract][Full Text] [Related]
12. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.
Pérez-Ruiz E; Rueda A; Pereda T; Alcaide J; Bautista D; Rivas-Ruiz F; Villatoro R; Pérez D; Redondo M
Tumour Biol; 2012 Dec; 33(6):1829-35. PubMed ID: 22791568
[TBL] [Abstract][Full Text] [Related]
13. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
[TBL] [Abstract][Full Text] [Related]
14. Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.
Rui YY; Zhang D; Zhou ZG; Wang C; Yang L; Yu YY; Chen HN
PLoS One; 2013; 8(10):e77901. PubMed ID: 24205021
[TBL] [Abstract][Full Text] [Related]
15. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
Ines C; Donia O; Rahma B; Ben Ammar A; Sameh A; Khalfallah T; Abdelmajid BH; Sabeh M; Saadia B
Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
[TBL] [Abstract][Full Text] [Related]
16. The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma.
Al-Allawi NA; Ismaeel AT; Ahmed NY; Merza NS
Indian J Cancer; 2012; 49(1):163-8. PubMed ID: 22842183
[TBL] [Abstract][Full Text] [Related]
17. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
18. [Identification of K-RAS mutations in colorectal cancer patients in Israel].
Segal G; Liebermann N; Klang S; Siegelmann-Daniel N; Beit-Or A; Klien B; Shoushan-Gutman L
Harefuah; 2011 May; 150(5):447-50, 491. PubMed ID: 21678640
[TBL] [Abstract][Full Text] [Related]
19. K-ras mutations in colorectal cancer: a practice changing discovery.
Saif MW; Shah M
Clin Adv Hematol Oncol; 2009 Jan; 7(1):45-53, 64. PubMed ID: 19274041
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
